Kopran Limited

BSE: 524280 NSE: KOPRAN
Kopran Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH1958PLC011078 Incorporated 26 April 1958 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: KOPRAN · BSE: 524280 Public Limited Company pharma
Data last updated
Market Cap
₹1,375 Cr
KOPRAN · NSE
Share Price
₹277.97
-2.31% today
Revenue
₹681 Cr
FY 2025-26 · +11.3% YoY
EBITDA
₹61.95 Cr
Margin 9.1%
Net Profit
₹25.73 Cr
FY 2025-26 · -33.2% YoY
P/E (TTM)
54.1x
P/B 2.6x
ROE
4.9%
ROCE 6.5%
Debt / Equity
0.29
Interest cover 23.5x

About Kopran Limited

Data last updated: 28 September 2026

Kopran Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 26 April 1958, the company has been in operation for over 68 years.

Registered with ROC Mumbai under CIN L24230MH1958PLC011078. Listed on BSE: 524280 and NSE: KOPRAN.

Capital: an authorised share capital of ₹70 Cr and a paid-up capital of ₹48.29 Cr. Formerly known as Kopran Chemical Company Private Limited. It is led by directors including Mamta Ashok Biyani and Narayan Tulsiram Atal.

Last AGM: 11 September 2025. Financial statements filed for year ended 31 March 2025. Office: Parijat House1076 Dr E Moses Road Worli Mumbai – 18, Maharashtra, India – 400018.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹681.42 Cr, a growth of 8.23% compared to the previous year. The net worth stands at ₹530.28 Cr (up 2.3% YoY). Total assets are valued at ₹691.91 Cr (up 2.2% YoY).

The company has a workforce of approximately 363 employees as per the latest available data. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand - Kopran. As per MCA filings, the company has open charges of ₹831.16 Cr and satisfied charges of ₹752.55 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website kopran.com.

Company Details of Kopran Limited
CIN L24230MH1958PLC011078
Registration Number 011078
Incorporation Date 26 April 1958
ROC Mumbai
Listing Status Listed (BSE: 524280, NSE: KOPRAN)
Company Status Active
Date of Last AGM 11 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Somani Surendra Managing Director Mamta Ashok Biyani Director Narayan Tulsiram Atal Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    kopran.com
  • Social Media
  • Registered Address
    Parijat House1076 Dr E Moses Road Worli Mumbai – 18, Maharashtra, India – 400018
  • Industry
    Pharma, Drug Formulation & Development
Company report
Kopran Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Kopran Limited report

Financials, compliance, directors, charges, ownership and filings for Kopran Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Kopran Limited

Kopran Limited operates one associated brand: Kopran. These brands represent Kopran Limited's diversified market presence and brand portfolio.

Brand Description Website
Kopran
Pharmaceutical Company manufacturing a range of products kopran.com

Competitors & Alternatives of Kopran Limited

Brands and companies operating in the same space as Kopran Limited include Concord Biotech, Almac Group, Indoco Remedies and 6 more.

Competitor Description Location Founded
Concord Biotech Concord Biotech APIs and enzymes are manufactured through fermentation by the CDMO. Ahmedabad, India, India 2000
Almac Group Almac Group Integrated CDMO services for biopharma R&D and manufacturing are offered. Craigavon, United Kingdom, United Kingdom 2001
Indoco Remedies Indoco Remedies APIs manufacturing and formulation services are provided in therapeutic segments. Mumbai, India, India 1947
Pharmaceutics International Pharmaceutics International Pharmaceutical dosage forms are manufactured by this CDMO. Hunt Valley, United States, United States 1994
Aurobindo Pharma Aurobindo Pharma Generic biocatalytic solutions are provided for pharmaceutical applications. Hyderabad, India, India 1986
Seqens Seqens Contract manufacturing services for small molecules and peptides are provided. Ecully, France, France 2003
Asymchem Asymchem APIs and peptides are developed and manufactured by Asymchem. Morrisville, United States, United States 1995
Aptuit Aptuit Contract research and development services for small molecules are offered. Greenwich, United States, United States 2004
Continuus Pharma Continuus Pharma MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development Woburn, United States, United States 2012

Business Activity of Kopran Limited

Kopran Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Kopran Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Kopran Limited

Kopran Limited is audited by KHANDELWAL JAIN & CO. for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
KHANDELWAL JAIN & CO. Locked Locked Locked
Premium access

Complete auditor history for Kopran Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Kopran Limited

Kopran Limited is currently managed by 6 directors, with 19 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Mamta Ashok Biyani
Also directs: Image Commercials Llp, Damodar Industries Limited, Oricon Enterprises Limited and 3 more
Director 08 May 2019 7 Years 4 Months Current
Narayan Tulsiram Atal
Also directs: International Conveyors Limited, Taparia Tools Limited, Gama Leafin Private Limited and 4 more
Director 08 May 2019 7 Years 4 Months Current
Somani Surendra
Also directs: Kopran Lifesciences Limited
Managing Director 11 Jun 1997 29 Years 3 Months Current
Varun Surendra Somani
Also directs: G Claridge And Company Limited, Kopran Laboratories Limited, Sorabh Trading Private Limited and 5 more
Director 29 May 2018 8 Years 3 Months Current
Chandresh Gunvant Gandhi
Also directs: Control Print Limited
Director 29 Jul 2025 1 Years 1 Months Current
Namrata Varun Somani
Also directs: Kopran Laboratories Limited, Sorabh Trading Private Limited, Apurva Caplease And Finance Private Limited and 3 more
Additional Director 19 May 2026 0 Years 4 Months Current
View all directors

Financials of Kopran Limited FY 2025-26 filings available

Kopran Limited reported revenue of ₹681.42 Cr (up 8.23% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹681 Cr
+8.2% YoY
EBITDA
₹61.95 Cr
-15.0% YoY
Profit After Tax
₹25.73 Cr
-33.2% YoY
Net Worth
₹530 Cr
+2.3% YoY
Total Assets
₹692 Cr
+2.2% YoY
Total Debt
₹153 Cr
+3.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue681630615551478492360
Revenue growth+11.3%+3.1%+8.2%+28.0%-4.9%+30.9%+0.6%
EBITDA61.9572.8874.4151.7987.3881.7746.14
EBITDA margin+9.1%+11.6%+12.1%+9.4%+18.3%+16.6%+12.8%
Profit before tax34.3651.9367.5436.0781.7683.3328.28
Net profit25.7338.5450.9527.2461.0161.6921.50
Net profit margin+3.8%+6.1%+8.3%+4.9%+12.8%+12.5%+6.0%
EPS (₹)5.337.9810.575.6512.6614.244.86
Balance sheet
Total assets692677599523509319285
Net worth530518491439426245190
Total debt15314899.2375.2474.5566.3188.28
Cash & bank7.2225.8614.2012.5857.136.904.75
Net working capital316352318279319161139
Cash flow
Cash from operations66.7541.9443.2634.02(33.48)59.9531.00
Cash from investing(64.60)(56.43)(43.55)(12.65)(84.42)(25.28)(12.52)
Cash from financing(20.94)25.870.99(19.84)123(34.57)(18.06)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue154234194118135172166152
Revenue growth (YoY)+13.9%+35.8%+16.9%-22.2%-3.0%-7.4%+4.6%-0.7%
Other income2.050.090.070.032.563.260.171.00
EBITDA15.8032.9517.76(5.28)14.1317.0819.8414.74
EBITDA margin+10.3%+14.1%+9.1%-4.5%+10.4%+9.9%+11.9%+9.7%
Depreciation5.774.524.424.284.263.874.003.85
Interest3.283.172.672.092.542.772.162.23
Profit before tax8.8025.3510.74(11.62)9.8913.7013.859.66
Tax2.106.481.40(1.70)2.444.033.462.26
Net profit6.7018.879.34(9.92)7.459.6710.397.40
EPS (₹)1.393.911.93(2.06)1.542.002.151.53
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue306271337273205223179
Revenue growth+11.1%-22.7%+22.6%+29.7%-1.8%+23.4%-10.2%
EBITDA47.5738.6536.9327.9015.4330.2023.17
EBITDA margin+15.6%+14.3%+10.9%+10.2%+7.5%+13.6%+12.9%
Profit before tax40.3935.7844.5236.9116.1932.7015.73
Net profit30.3926.8434.6531.2511.7723.4711.26
Net profit margin+9.9%+9.9%+10.3%+11.4%+5.8%+10.5%+6.3%
EPS (₹)6.305.567.186.482.445.432.59
Balance sheet
Total assets498482444428420266279
Net worth448431417396379247230
Total debt46.3645.3122.7127.8836.9015.7245.72
Cash & bank2.1821.027.422.592.553.221.15
Net working capital13714712411511055.8866.42
Cash flow
Cash from operations29.6623.3034.9616.87(37.80)48.779.97
Cash from investing(30.08)(15.41)(6.27)10.05(100)(8.51)0.63
Cash from financing(18.53)5.64(24.08)(26.13)138(40.14)(10.60)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue62.7611893.8842.3951.3375.9471.9473.53
Revenue growth (YoY)+22.3%+55.4%+30.5%-42.4%+3.5%-16.2%-12.6%-25.5%
Other income2.911.000.320.321.801.920.751.12
Total expenses54.3091.4576.2045.6046.2663.6560.5463.84
EBITDA8.4626.5917.68(3.21)5.0712.2911.409.69
EBITDA margin+13.5%+22.5%+18.8%-7.6%+9.9%+16.2%+15.8%+13.2%
Depreciation1.351.341.251.161.221.241.331.23
Interest1.241.171.160.831.041.260.990.83
Profit before tax8.7825.0815.59(4.88)4.6111.719.838.75
Tax2.066.333.45(0.88)1.093.112.422.15

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue154234194118135172166152
Revenue growth (YoY)+13.9%+35.8%+16.9%-22.2%-3.0%-7.4%+4.6%-0.7%
Other income2.050.090.070.032.563.260.171.00
EBITDA15.8032.9517.76(5.28)14.1317.0819.8414.74
EBITDA margin+10.3%+14.1%+9.1%-4.5%+10.4%+9.9%+11.9%+9.7%
Depreciation5.774.524.424.284.263.874.003.85
Interest3.283.172.672.092.542.772.162.23
Profit before tax8.8025.3510.74(11.62)9.8913.7013.859.66
Tax2.106.481.40(1.70)2.444.033.462.26
Net profit6.7018.879.34(9.92)7.459.6710.397.40
EPS (₹)1.393.911.93(2.06)1.542.002.151.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue681630615551478492360
Revenue growth+11.3%+3.1%+8.2%+28.0%-4.9%+30.9%+0.6%
Other income0.353.9814.613.0710.6017.990.63
Total expenses619557540499390410313
Employee cost65.2160.5452.2849.9543.2737.1636.85
EBITDA61.9572.8874.4151.7987.3881.7746.14
EBITDA margin+9.1%+11.6%+12.1%+9.4%+18.3%+16.6%+12.8%
Depreciation17.4715.5912.8912.7111.1010.199.58
Interest10.479.348.596.085.126.248.91
Profit before tax34.3651.9367.5436.0781.7683.3328.28
Tax8.6313.3916.598.8320.7521.737.27
Net profit25.7338.5450.9527.2461.0161.6921.50
Net profit margin+3.8%+6.1%+8.3%+4.9%+12.8%+12.5%+6.0%
EPS (₹)5.337.9810.575.6512.6614.244.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital48.2948.2948.2148.2148.2143.2543.25
Reserves & surplus482470443391378202146
Shareholders' funds (net worth)530518491439426245190
Minority interest0.000.000.000.000.000.000.00
Secured loans13013383.0557.9855.6461.3362.88
Unsecured loans22.7214.4716.1817.2618.914.9825.40
Total debt15314899.2375.2474.5566.3188.28
Total liabilities692677599523509319285
Assets
Gross block461306263234207157146
Net block346208182165151112111
Capital work in progress24.7911396.5969.5835.5542.8930.24
Investments0.060.060.060.060.060.050.02
Inventories16416913813115010088.50
Sundry debtors26321521216312712092.81
Cash & bank balances7.2225.8614.2012.5857.136.904.75
Loans & advances89.0999.5389.0293.3280.4449.9736.55
Total current assets523510454399415277223
Total current liabilities20715813612095.8011683.61
Net working capital316352318279319161139
Total assets692677599523509319285
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19.478.097.405.870.940.830.41
Net cash from operating activities66.7541.9443.2634.02(33.48)59.9531.00
Net cash from investing activities(64.60)(56.43)(43.55)(12.65)(84.42)(25.28)(12.52)
Net cash from financing activities(20.94)25.870.99(19.84)123(34.57)(18.06)
Net change in cash(18.79)11.380.691.534.930.100.42
Closing cash7.2225.8614.2012.5857.136.904.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+8.2%+2.4%+11.5%+15.4%-2.9%+36.8%+0.5%
EBITDA growth-15.0%-2.1%+43.7%-40.7%+6.9%+77.2%-0.4%
PBT growth-33.8%-23.1%+87.3%-55.9%-1.9%+194.7%-10.7%
Net income growth-33.2%-24.4%+87.0%-55.4%-1.1%+186.9%-10.6%
Revenue CAGR (3Y)+7.3%+9.7%+7.7%+15.3%+10.1%+16.2%+5.1%
EBITDA CAGR (3Y)+6.2%-5.9%-3.1%+3.9%+23.6%+39.1%+8.6%
Profitability & leverage
Net income margin+3.8%+6.1%+8.3%+4.9%+12.8%+12.5%+5.8%
Return on capital employed+6.6%+9.6%+13.6%+8.2%+21.0%+29.6%+12.8%
Return on net worth+4.9%+7.6%+11.0%+6.3%+18.2%+28.3%+11.1%
Debt / equity0.290.240.190.170.210.360.49
Long-term debt / equity0.030.030.030.040.050.110.16
Interest cover23.5416.3013.9615.566.718.7224.37
Efficiency & per share
Fixed asset turnover1.782.212.472.502.623.242.53
Inventory turnover4.084.094.573.933.825.224.44
Debtors turnover2.852.953.283.803.864.624.01
EPS (₹)5.337.9810.575.6512.6614.244.86
Dividend per share (₹)3.003.003.003.003.003.000.00
Book value per share (₹)109.82107.35101.9091.1188.4056.6543.86
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue62.7611893.8842.3951.3375.9471.9473.53
Revenue growth (YoY)+22.3%+55.4%+30.5%-42.4%+3.5%-16.2%-12.6%-25.5%
Other income2.911.000.320.321.801.920.751.12
Total expenses54.3091.4576.2045.6046.2663.6560.5463.84
EBITDA8.4626.5917.68(3.21)5.0712.2911.409.69
EBITDA margin+13.5%+22.5%+18.8%-7.6%+9.9%+16.2%+15.8%+13.2%
Depreciation1.351.341.251.161.221.241.331.23
Interest1.241.171.160.831.041.260.990.83
Profit before tax8.7825.0815.59(4.88)4.6111.719.838.75
Tax2.066.333.45(0.88)1.093.112.422.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue306271337273205223179
Revenue growth+11.1%-22.7%+22.6%+29.7%-1.8%+23.4%-10.2%
Other income2.005.9016.7116.098.0310.411.99
Total expenses258232301245189193156
Employee cost32.9430.0225.6125.1521.0518.3420.02
EBITDA47.5738.6536.9327.9015.4330.2023.17
EBITDA margin+15.6%+14.3%+10.9%+10.2%+7.5%+13.6%+12.9%
Depreciation4.985.004.624.414.324.103.47
Interest4.203.774.502.672.953.815.96
Profit before tax40.3935.7844.5236.9116.1932.7015.73
Tax10.008.949.885.664.429.244.51
Net profit30.3926.8434.6531.2511.7723.4711.26
Net profit margin+9.9%+9.9%+10.3%+11.4%+5.8%+10.5%+6.3%
EPS (₹)6.305.567.186.482.445.432.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital48.2948.2948.2148.2148.2143.2543.25
Reserves & surplus400383369347331204186
Shareholders' funds (net worth)448431417396379247230
Secured loans44.3643.3120.7125.8826.8212.7214.40
Unsecured loans2.002.002.002.0010.083.0031.32
Total debt46.3645.3122.7127.8836.9015.7245.72
Total liabilities498482444428420266279
Assets
Gross block12296.6782.4673.1767.6364.6056.00
Net block81.8861.4552.0247.3546.2247.4442.95
Capital work in progress7.597.444.703.533.102.827.07
Investments265263261260259159158
Inventories65.8555.7549.4947.6041.5127.5041.17
Sundry debtors13391.9287.8083.8159.1349.4642.48
Cash & bank balances2.1821.027.422.592.553.221.15
Loans & advances39.6440.3642.9956.4048.1130.9229.44
Total current assets240209188190151111114
Total current liabilities10461.5764.0675.2941.4355.2247.82
Net working capital13714712411511055.8866.42
Total assets498482444428420266279
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash19.185.651.040.250.320.210.21
Net cash from operating activities29.6623.3034.9616.87(37.80)48.779.97
Net cash from investing activities(30.08)(15.41)(6.27)10.05(100)(8.51)0.63
Net cash from financing activities(18.53)5.64(24.08)(26.13)138(40.14)(10.60)
Net change in cash(18.95)13.534.610.79(0.07)0.120.00
Closing cash2.1821.027.422.592.553.221.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.8%-19.7%+23.6%+33.5%-8.2%+24.3%-8.8%
EBITDA growth+23.1%+4.7%+32.4%+80.8%-48.9%+30.3%+1.5%
PBT growth+12.9%-19.6%+20.6%+128.0%-50.5%+107.9%-9.4%
Net income growth+13.2%-22.5%+10.9%+165.5%-49.9%+108.4%-13.5%
Revenue CAGR (3Y)+3.8%+9.8%+14.8%+15.1%+1.3%+13.2%-0.4%
EBITDA CAGR (3Y)+19.5%+35.8%+6.9%+6.4%-12.2%+49.9%+10.1%
Profitability & leverage
Net income margin+9.9%+9.9%+10.3%+11.4%+5.8%+10.5%+6.3%
Return on capital employed+9.1%+8.5%+11.2%+9.3%+5.6%+13.4%+7.9%
Return on net worth+6.9%+6.3%+8.5%+8.1%+3.8%+9.9%+5.0%
Debt / equity0.100.080.060.080.080.130.20
Long-term debt / equity0.000.000.000.000.000.010.04
Interest cover9.8611.2013.9311.3726.5514.6030.25
Efficiency & per share
Fixed asset turnover2.803.034.343.883.093.703.34
Inventory turnover5.035.156.956.135.936.495.40
Debtors turnover2.723.023.933.823.774.854.12
EPS (₹)6.305.567.186.482.445.432.59
Dividend per share (₹)3.003.003.003.003.003.000.00
Book value per share (₹)92.7589.3586.4782.0578.5657.0753.10
Want more history and ratios?
You're viewing the latest exchange-filed financials for Kopran Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Kopran Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 44.40%, foreign institutional investors hold 0.50%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 55.10% of Kopran Limited.

Promoters: 44.40%FII (Foreign Institutional): 0.50%Retail & Others: 55.10%
Jun 2026
QUARTER
44.40% Promoters
0.50% FII (Foreign Institutional)
55.10% Retail & Others
Promoter holding - history
Now 44.40% · Jun 2026High 44.40% · Sep 2025Low 44.40% · Sep 2025
43%43.8%44.5%45.3%46%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 44.40%Dec 2025: 44.40%Mar 2026: 44.40%Jun 2026: 44.40%44.40%44.40%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters44.40%44.40%44.40%44.40%
Public55.60%55.60%55.60%55.60%

Group Structure of Kopran Limited

Kopran Limited has 2 subsidiary companies. This group structure data is as of FY 2023. The corporate group structure reflects Kopran Limited's business expansion strategy and organizational complexity.

2
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Kopran Research Laboratories Limited U24230MH1986PLC040601 -
Kopran Lifesciences Limited U74120MH2010PLC211125 -

Showing major subsidiaries. Total: 2.

Charges & Borrowings of Kopran Limited

Open charges
₹831.16 Cr
Satisfied charges
₹752.55 Cr
Breakdown by lending institutions
State Bank of India₹370.65 Cr
Import Export Bank of India₹300.00 Cr
Sbicap Trustee Company Limited₹69.25 Cr
Export-Import Banbk of India₹15.00 Cr
The Hong Kong and Shanghai Banking Corporation Ltd₹10.00 Cr
Others₹66.26 Cr
Latest charge details
DateLenderAmountStatus
30 Jul 2020 State Bank of India ₹124.75 Cr Open
26 Dec 2014 State Bank of India ₹3.5 Cr Open
28 Jan 2013 State Bank of India ₹11.5 Cr Open
04 Jul 2007 Canara Bank ₹8 Cr Open
10 Aug 2005 State Bank of India ₹2.6 Cr Open

Total charge records: 108 View all charges

Employees and EPFO Compliance at Kopran Limited

Kopran Limited has a workforce of 363 employees as of Apr 02, 2024.

Employee count
363
Active EPFO establishments
1
Employee growth
-11.46%
Premium access

Employee and EPFO history for Kopran Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Kopran Limited

Premium access

GST registrations and filing compliance for Kopran Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Kopran Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Kopran Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Kopran Limited

Premium access

MSME payment history for Kopran Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Kopran Limited

Premium access

Corporate group structure for Kopran Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Kopran Limited

Premium access

MCA filings and documents for Kopran Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Kopran Limited

Directors
19 May 2026
Namrata Varun Somani was appointed as a Additional Director on 19 May 2026 & has been associated with this company since 4 months 12 days.
Charges
06 Mar 2026
A charge registered on 12 Aug 1994 via Charge ID 90222371 with The Industrail Credit And Investment Corporation Of Indai Lt was fully satisfied on 06 Mar 2026.
Charges
06 Mar 2026
A charge registered on 14 Feb 1994 via Charge ID 90222291 with The Industrail Credit And Investment Corporation Of India Lt was fully satisfied on 06 Mar 2026.
Charges
06 Mar 2026
A charge registered on 11 Feb 1993 via Charge ID 90222149 with The Bank Of Rajastahn Ltd. was fully satisfied on 06 Mar 2026.
Charges
06 Mar 2026
A charge registered on 08 Apr 1992 via Charge ID 90222047 with The Industrail Credit And Investment Corporation Of India Lt was fully satisfied on 06 Mar 2026.
Charges
06 Mar 2026
A charge registered on 13 Nov 1991 via Charge ID 90221984 with The Bank Of Rajasthan Ltd. was fully satisfied on 06 Mar 2026.

Recent News on Kopran Limited

Change in Secretarial Auditors of Kopran
09 May 2019 · Business Standard

Frequently Asked Questions about Kopran Limited

Kopran Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 26 April 1958 (68+ years old) and is registered under CIN L24230MH1958PLC011078. Listed on BSE: 524280 and NSE: KOPRAN. The company has 363 employees.

Kopran Limited reported revenue of ₹681.42 Cr for FY 2025-26 (up 8.23% YoY) based on consolidated financials.

The current directors of Kopran Limited are:

The primary industry of Kopran Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Kopran Limited is listed on both BSE (code: 524280) and NSE (symbol: KOPRAN).

Kopran Limited can be reached at the registered office: Parijat House1076 Dr E Moses Road Worli Mumbai – 18, Maharashtra, India – 400018, or through the website kopran.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available